{{expand|time=2017-12-24T17:28:09+00:00}}
{{unreferenced|time=2013-02-15T15:17:04+00:00}}
{{Drugbox
| verifiedrevid = 459430179
| IUPAC_name = (''RS'')-5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
| image = Hexobarbital.png
| width = 200px
| imagename = 1 : 1 mixture (racemate)
| drug_name = 环己巴比妥

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 25%
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 56-29-1
| CAS_supplemental = <br/>{{CAS|50-09-9}} (sodium salt)
| ATC_prefix = N01
| ATC_suffix = AF02
| ATC_supplemental =  {{ATC|N05|CA16}}
| PubChem = 3608
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01355
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3482
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AL8Z8K3P6S
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01071
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5706
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 7728

<!--Chemical data-->
| C=12 | H=16 | N=2 | O=3 
| molecular_weight = 236.267 g/mol
| smiles = O=C1N(C(=O)NC(=O)C1(/C2=C/CCCC2)C)C
| InChI = 1/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
| InChIKey = UYXAWHWODHRRMR-UHFFFAOYAQ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UYXAWHWODHRRMR-UHFFFAOYSA-N
}}

'''环己巴比妥'''({{lang|en|Hexobarbital}}、{{lang|en|hexobarbitone}})是一种具有[[镇静|镇静]]和[[催眠|催眠]]效果的[[巴比妥|巴比妥]]衍生物。在20世纪40至50年代用于外科手术[[麻醉|麻醉]]，因为它起效快、催睡时间短并且代谢迅速。但使用环己巴比妥很难控制麻醉的深度，故有时非常危险。现时采用的麻醉药物更加安全，在巴比妥类药物中，[[戊硫代巴比妥|戊硫代巴比妥]]代替了环己巴比妥。但有时巴比妥仍被用于科学研究中。

==延伸閱讀==
{{refbegin}}
* {{cite journal|title=[New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases]|pages=857–871|issn=0031-6903|journal=Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan|volume=124|issue=12|date=2004-12|url=https://www.ncbi.nlm.nih.gov/pubmed/15577260|accessdate=2019-02-13|author=Reiko Takenoshita, Satoshi Toki|pmid=15577260}}
* {{cite journal|title=A study of the duration of acute tolerance induced with hexobarbital in male rats|pages=945–948|issn=0091-3057|journal=Pharmacology, Biochemistry, and Behavior|volume=59|issue=4|date=1998-4|url=https://www.ncbi.nlm.nih.gov/pubmed/9586853|accessdate=2019-02-13|author=G. Wahlström|pmid=9586853}}
* {{cite journal|title=Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat|pages=371–377|issn=0006-8993|journal=Brain Research|volume=676|issue=2|date=1995-04-10|url=https://www.ncbi.nlm.nih.gov/pubmed/7614008|accessdate=2019-02-13|author=S. Korkmaz, E. Ljungblad, G. Wahlström|pmid=7614008}}
* {{cite journal|title=Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital|pages=73–76|issn=0091-3057|journal=Pharmacology, Biochemistry, and Behavior|volume=46|issue=1|date=1993-9|url=https://www.ncbi.nlm.nih.gov/pubmed/8255925|accessdate=2019-02-13|author=V. Dall, U. Orntoft, A. Schmidt, L. Nordholm|pmid=8255925}}
{{refend}}

{{Barbiturates}}
{{General anesthetics}}
{{Hypnotics and sedatives}}

[[Category:麻醉药|Category:麻醉药]]